

# NSCLC: 2024 highlights and key market-impacting events to watch in 2025

Market Trend Summary

# Select 2024 highlights

## Immune checkpoint inhibitors

- **Tecentriq Hybreza** approved as first subcutaneous PD-(L)1 inhibitor in NSCLC
- Early-stage resectable setting sees approval of perioperative **Opdivo** and **Imfinzi**

## EGFR-targeting agents

- **Tagrisso** enters unresectable stage III setting
- Approval of first-line **Tagrisso** + chemotherapy
- **Rybrevant + Lazcluze** approved in first-line
- **Rybrevant** + chemotherapy moves into first line for *EGFR* exon 20 insertion mutations, and enters later-line for classic *EGFR* mutations

## ALK inhibitors

- **Alecensa** enters early-stage resectable setting

## HER2×HER3-targeted agents

- **Zenocutuzumab** approved in later-line metastatic *NRG1*-positive NSCLC - a niche population with an unmet need

# Select market-impacting events expected in 2025



## Anticipated regulatory decisions on select filings under review

- **By early 2025:** EC decision on positive CHMP recommendations issued in November 2024: **Tagrisso**; **Rybrevant + Lazcluze**; **Augtyro**
- **Mid-2025:** **Subcutaneous Rybrevant** across various *EGFR*-mutation settings; the SC formulation significantly reduces administration time
- **Mid-2025:** The MET-targeting ADC **telisotuzumab vedotin** for previously treated advanced nonsquamous *EGFR*-wild-type patients with MET overexpression, an untapped setting



## Notable clinical trial data read-outs to watch<sup>1</sup>

- **June 2025:** Phase 3 DESTINY-Lung04 trial of the HER2-targeting ADC **Enhertu** for the first-line treatment of patients with *HER2* mutations, who currently lack HER2-targeting options in the first-line setting
- **December 2025:** Phase 3 HARMONi trial of the PD-1×VEGF bispecific **ivonescimab** + chemotherapy in *EGFR*-mutated patients after prior *EGFR* inhibitor therapy



## Major conferences to watch for NSCLC

- **March 2025:** European Lung Cancer Congress
- **May-June 2025:** ASCO Annual Meeting
- **September 2025:** World Conference on Lung Cancer
- **October 2025:** ESMO Congress

# About the author



## Charlotte Jago, Ph.D.

### Senior Healthcare Research & Data Analyst

Charlotte Jago is a pharmaceutical industry analyst with more than 20 years' experience, preceded by 5 years of laboratory research in academia (Imperial College London) and industry (Celltech, now UCB). She wrote the flagship Cortellis Drugs to Watch reports in 2013, 2014, 2015, and 2019 and led the improvement in immuno-oncology coverage on the Cortellis Competitive Intelligence platform. She holds a Ph.D. in immunology, a first-class degree in pharmacology, and a postgraduate certificate in journalism.

### Clarivate coverage of NSCLC

- NSCLC *Disease Landscape & Forecast (G7)*.
  - Provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, and drug forecasts supported by detailed primary and secondary research
- NSCLC *Current Treatment: Physician Insights: US*
  - Provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use in NSCLC
- NSCLC *Current Treatment: Treatment Sequencing: US*
  - Provides sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey in NSCLC
- NSCLC *Unmet Need: US/EU*
  - Provides insights into areas of unmet need in specific subpopulations



# Think forward™

Have a question?

[healthcare.support@clarivate.com](mailto:healthcare.support@clarivate.com)  
[clarivate.com](https://clarivate.com)

+1 215 386 0100 (U.S.)  
+44 (0) 20 7433 4000 (Europe)

## About Clarivate

Clarivate is the leading global information services provider. We connect people and organizations to intelligence they can trust to transform their perspective, their work and our world. Our subscription and technology-based solutions are coupled with deep domain expertise and cover the areas of Academia & Government, Life Sciences & Healthcare and Intellectual Property. For more information, please visit [clarivate.com](https://clarivate.com)

© 2024 Clarivate. All rights reserved

Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.